Comparing Revenue Performance: Teva Pharmaceutical Industries Limited or Perrigo Company plc?

Teva vs. Perrigo: A Decade of Revenue Trends

__timestampPerrigo Company plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014406080000020272000000
Thursday, January 1, 2015460390000019652000000
Friday, January 1, 2016528060000021903000000
Sunday, January 1, 2017494620000022385000000
Monday, January 1, 2018473170000018854000000
Tuesday, January 1, 2019483740000016887000000
Wednesday, January 1, 2020506330000016658000000
Friday, January 1, 2021413870000015878000000
Saturday, January 1, 2022445160000014925000000
Sunday, January 1, 2023465560000015846000000
Monday, January 1, 202416544000000
Loading chart...

Igniting the spark of knowledge

A Decade of Revenue: Teva vs. Perrigo

In the competitive landscape of pharmaceuticals, Teva Pharmaceutical Industries Limited and Perrigo Company plc have been key players. From 2014 to 2023, Teva consistently outperformed Perrigo in revenue, despite a notable decline. Teva's revenue peaked in 2017, reaching approximately $22.4 billion, before experiencing a downward trend, closing at around $15.8 billion in 2023. This represents a 29% decrease over the decade.

Conversely, Perrigo's revenue remained relatively stable, fluctuating between $4 billion and $5.3 billion. The company saw its highest revenue in 2016, with a slight dip in subsequent years, ending 2023 with a revenue of about $4.7 billion. This stability highlights Perrigo's resilience in a volatile market.

The data underscores the contrasting revenue trajectories of these pharmaceutical giants, offering insights into their strategic positioning and market adaptability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025